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Microglia is increasingly recognized to play a crucial role in the pathogenesis of
psychiatric diseases. In particular, microglia may be the cellular link between inflammation
and behavioral alterations: by releasing a number of soluble factors, among which
pro-inflammatory cytokines, that can regulate synaptic activity, thereby leading to
perturbation of behavior. In multiple sclerosis (MS), the most common neuroinflammatory
disorder affecting young adults, microglia activation and dysfunction may account for
mood symptoms, like depression and anxiety, that are often diagnosed in patients
even in the absence of motor disability. Behavioral studies in experimental autoimmune
encephalomyelitis (EAE), the animal model of MS, have shown that emotional
changes occur early in the disease and in correlation to inflammatory mediator and
neurotransmitter level alterations. However, such studies lack a full and comprehensive
analysis of the role played by microglia in EAE-behavioral syndrome. We review the
experimental studies addressing behavioral symptoms in EAE, and propose the study
of neuron-glia interaction as a powerful but still poorly explored tool to investigate the
burden of microglia in mood alterations associated to MS.
Keywords: microglia, experimental autoimmune encephalomyelitis, multiple sclerosis, behavioral syndrome,
neuron-microglia interaction, depression, anxiety
Introduction
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease of
the central nervous system (CNS), which represents the leading cause of non-traumatic disability
in young adults in Western countries (Compston and Coles, 2008). In addition to physical
impairment, MS is frequently associated to mood disorders, like anxiety and depression even
in non-disabled patients (Marrie et al., 2009). Structural and functional brain changes, induced
by inflammation, seem to be implicated in MS psychiatric symptoms (Feinstein et al., 2014).
In fact, T-lymphocytes peripherally primed against myelin-like components infiltrate the brain
and initiate a chain of inflammatory events, including both gray and white matter microgliosis
(Centonze et al., 2010). Interestingly, recent studies in MS animal model, the experimental
autoimmune encephalomyelitis (EAE), have shown that activated microglia, by releasing pro-
inflammatory cytokines, can alter brain synaptic transmission also before the appearance of
motor symptoms (Centonze et al., 2009, 2010). Notably, changes in neuronal compartment
and abnormalities in microglial physiology have been related to several psychopathological
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conditions in both humans and animal models (Price and
Drevets, 2010; Frick et al., 2013), raising the possibility that
microglia may have a crucial role in mediating mood disorders
in MS.
This paper briefly discusses the current studies about
anxious- and depressive-like behaviors in the EAE model
and proposes the contribution of microglia to EAE mood
disorders, as an important but quite unexplored field for future
research.
Microglia in Mood Disorders
Microglia derive frommacrophage lineage and represent 10–20%
of the glial cells in the CNS (Lynch, 2009). Exposure to foreign
antigens or cellular debris induces microglial cytotoxic activation
required for brain immune surveillance. Such activated microglia
release a variety of proinflammatory mediators, like interleukin-
1β (IL-1β) and tumor necrosis factor (TNF; Lynch, 2009;
Kettenmann et al., 2011).
However, cytokines, such as interleukin-4 (IL-4) or
interleukin-25 (IL-25), can shift microglial state from the
resting to the neuroprotective one (Zhou et al., 2012;
Maiorino et al., 2013). Activated microglia can switch from
the characteristic ramified morphology to the hyperramified or
amoeboid/phagocytic one with upregulation of several markers,
including the ionized calcium-binding adapter molecule 1 (Iba1)
and CD11b (Kettenmann et al., 2011).
Microglia mutually interact by contact or via mediators
with several cells, like T cells, astrocytes and even neurons
and such interactions can induce changes in microglial state
(Lynch, 2009). The direct and indirect communication between
microglia and neurons reveals microglia synaptic functions in
addition to the well-established immune ones. In fact, it has
been demonstrated that microglia participate in neurogenesis
(Butovsky et al., 2006), neuronal transmission (Graeber, 2010)
and synaptic pruning inmemory and neuronal plasticity (Schafer
et al., 2012).
Both abnormalities in microglial physiology and dysfunction
of neuron-microglia cross-talk have been involved in psychiatric
diseases. For example, several postmortem studies have reported
abundant activated microglia surrounding neurons (Vargas
et al., 2005) and a switch to amoeboid morphology (Morgan
et al., 2010; Tetreault et al., 2012) in multiple brain regions
from patient with autism spectrum disorders. Moreover,
positron emission tomography (PET) imaging has confirmed
postmortem findings about microglial activation in autism
patients (Suzuki et al., 2013). Similar results have been
observed in different animal models of autism (Zerrate et al.,
2007; Heo et al., 2011; MacFabe et al., 2011). Furthermore,
a recent work in MECP2-null mice, which model Rett
syndrome, an X-linked autism spectrum disorder, has provided
one of the first causal links between microglial alterations
and psychiatric disturbances: the authors succeeded in the
mitigation of Rett syndrome-like symptoms by supplying
wild-type microglia through bone marrow transplantation
or genetic rescue in MECP2-null mice (Derecki et al.,
2012).
A role formicroglia in anxiety and depression is also emerging
on the basis of several observations. First, IL-1β and TNF,
which are proinflammatory cytokines released during peripheral
infection as well as by activated microglia, can induce sickness
behavior, resulting in decreased motor activity, fatigue, reduced
food intake, anhedonia and social withdrawal in both rodents
and humans. Many of these symptoms are commonly observed
in depressed patients (Dantzer et al., 2008), whose levels of
proinflammatory cytokines have been found increased in both
peripheral blood and cerebrospinal fluid (CSF; Zorrilla et al.,
2001). Second, postmortem studies have revealed consistent
microgliosis in suicide-attempters compared to controls (Steiner
et al., 2008). Moreover, both activation state of microglia and
proinflammatory cytokine levels have been suggested to predict
depression relapse and, even, to evaluate the therapeutic response
(Miller et al., 2009; Munkholm et al., 2013; Watkins et al.,
2014).
Studies on animal models have provided further evidence
for involvement of microglia in the pathogenesis of anxious-
and depressive-like behaviors. Rodent paradigms of chronic
stress, such as repeated constrain or repeated social defeat, have
been reported to induce anxious- and depressive-like symptoms,
associated to changes in both microglial activation state and
morphology in several brain regions (Tynan et al., 2010; Wohleb
et al., 2011; Hinwood et al., 2013). Notably, the treatment
of stressed animals with the antibiotic minocycline is able to
recover microglial homeostasis together with mood dysfunctions
(Hinwood et al., 2013).
Both preclinical and clinical data support the theory of the
inflammatory etiology for anxious and depressive behavior, and
implicate microglia as possible cellular mediators of these mental
disorders (Eyre and Baune, 2012).
EAE Models Behavioral Symptoms of MS
Although it is reasonable to expect that mood alterations in
MS patients are a consequence of their physical progressive
disability, the prevalence of anxiety and depression, is generally
higher in persons with MS with respect to both the general
population (Patten et al., 2003) and patients with other
neurological disorders (Schiffer and Babigian, 1984; Schubert
and Foliart, 1993; Thielscher et al., 2013). In some cases,
psychiatric symptoms may occur at the onset of the disease
and independently of physical disability (Haussleiter et al.,
2009; Lo Fermo et al., 2010; Suh et al., 2010; Rietberg et al.,
2011).
While physical disability is the primary target of
pharmacological treatment, mood disorders are currently
undervalued and undertreated in clinical practice (Marrie
et al., 2009), although they can dramatically worsen the
quality of life of MS patients. The scarce attention paid to
the psychiatric aspects of MS symptomatology is in part due
to the lack of knowledge of their pathological basis. In this
respect, studies in animal models of MS may represent the
unique opportunity to address this critical issue. Although
many of the clinical features of mental illness generally cannot
be modeled in rodents, some animal models of depression
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and anxiety provide reliable and measurable correlate of
human behavior and allow the study of their molecular
underpinnings. Most of MS clinical and histopathological
features are well shaped by EAE, in particular the myelin
oligodendrocyte glycoprotein p35–55 (MOG35–55)-induced
‘‘chronic’’ EAE in C57BL/6 mice (Furlan et al., 2009). In such
model different phases of the disease can be distinguished:
the pre-symptomatic phase with absence of motor deficits,
the acute phase starting from the onset to the peak of clinical
symptoms and the following chronic phase, in which motor
symptoms become milder. Several studies have reported both
anxiety- and depression-like behaviors in all EAE clinical phases
in correlation with a number of cellular and molecular players
(Table 1).
Former studies by Pollak and colleagues characterized the
so-called ‘‘sickness behavior’’ in EAE mice (Pollak et al., 2000,
2003a,b). All the hallmarks of sickness behavior, observed in
acute-phase-EAE mice, were recovered in later phases of the
disease, with the exception of the body weight. Notably, such
behavior affected EAE mice from the day before the onset of
neurological symptoms, demonstrating that emotional changes
in EAE are not the mere consequence of motor disability
(Pollak et al., 2000). Also, chronic treatment with anti-depressant
imipramine prevented body-weight loss in EAE mice (Pollak
et al., 2002).
Next, they found that the onset of behavioral syndrome
coincided with elevation of TNF and IL-1β in the brain
and prostaglandin E2 (PGE2) in the hypothalamus (Pollak
et al., 2003a). Interestingly, pro-inflammatory cytokines reached
their peak expression in the sickness-behavior phase and
decreased along with behavioral recovery, which correlated with
worsening of motor symptoms, confirming the hypothesis that
cytokines sustain the initial process leading to neurological
symptoms but their role dampens with time. Moreover, mice
showing sickness behavior but lacking neurological deficits had
cerebellar levels of cytokines comparable to motor impaired
and behaviorally sick mice, corroborating previous observations
(Pollak et al., 2000) and linking for the first time behavioral
alterations and inflammation in EAE. However, neither the
cellular source of cytokines nor the cytokine levels in EAE mice
prior to the behavioral depression were investigated. By using
different anti-inflammatory approaches aimed at blocking IL-
1β, TNF and PGE2 signaling, they further demonstrated the
correlation between inflammation and sickness behavior (Pollak
et al., 2003b). Notably, the treatment against TNF signaling
was ineffective if administered alone, but when associated to
IL-1β antagonist (IL-1ra) improved the effect of IL-1ra on
behavior, suggesting a synergistic interaction between the two
cytokines.
The picture herein described is limited to sickness
behavior, which is a phenotypic trait of depression-
and anxiety-like behaviors in both humans and rodents
(Dantzer et al., 2008). Several ethological paradigms have
been developed to assess such behaviors in rodents and
some of them have been used to characterize EAE-linked
behavioral syndrome. Peruga and colleagues demonstrated
both anxiety- and depressive-like behaviors in mice with
mild-EAE phenotype (only with tail weakness) during the
acute and chronic phases, through well-established behavioral
paradigms requiring regular motor abilities, like open field
test (OFT), light-dark test (LDT), startle response test
(SR) for anxious-like behavior, pre-pulse inhibition (PPI)
and learned helpless test (LH) for depressive-like behavior
(Peruga et al., 2011). The emotional changes observed in
EAE mice were associated with inflammation (lymphocyte
infiltration, microglia activation and TNF expression) in
peri-hippocampal regions and a significant and progressive
neuronal loss in CA1 hippocampal region. Also, although
monoaminergic neurotransmitters were not significantly
changed in EAE hippocampus, amytriptiline treatment
significantly increased norepinephrine levels and attenuated
behavioral response. Musgrave and colleagues also addressed
a role for catecholamine in EAE-behavioral syndrome: the
anti-depressant phenelzine (PLZ) improved EAE motor
disability and behavioral performance in the OFT and corrected
altered monoamine levels in several brain areas, without
affecting microgliosis in the spinal cord (Musgrave et al.,
2011). Therefore, they suggested that the behavioral response
to PLZ observed in EAE is likely due to normalization of
serotonin levels in ventral horn of spinal cord. Although valid,
such interpretation lacks information about microgliosis and
inflammation in brain areas more likely involved in mood
control.
In a study published in 2012, we showed anxiety-like behavior
in pre-symptomatic EAE mice (Haji et al., 2012) by OFT and
elevated plus maze (EPM) behavioral tasks. Interestingly,
such behavior was associated with strong microglia activation,
increased TNF levels and potentiated glutamatergic transmission
in the striatum of EAE mice. Preventive intracerebroventricular
blockade of TNF had anxiolytic-like effect on EAE mice and
normalized glutamatergic transmission. Notably, the striatum
is a subcortical area involved in MS and EAE (Bermel et al.,
2003; Centonze et al., 2009) as well as in mood control
(Báez-Mendoza and Schultz, 2013) and striatal glutamatergic
transmission alterations already occurs in pre-symptomatic
phase (Centonze et al., 2009), suggesting that synaptic
dysregulation in this area may account for EAE behavioral
changes.
In contrast, others did not detect any signs of anxiety-
like behavior in both pre-symptomatic and acute EAE mice
at the EPM (Rodrigues et al., 2011). Conversely, Acharjee
and colleagues confirmed our findings and showed for
the first time depressive-like behavior in pre-symptomatic
EAE mice, through classical paradigms for depressive-
like behavior in rodents, the tail suspension (TST) and
the forced swimming tests (FST; Acharjee et al., 2013).
The authors correlated emotional impairment in EAE
mice with increased expression of IL-1β and TNF in the
hypothalamus. They did detect neither astro-nor microgliosis in
the hypothalamus, the amygdala and the hippocampus of EAE
brains, concluding that EAE emotional changes were linked
to alteration of hypothalamic-pituitary-adrenal axis (HPA),
as already suggested for the acute phase of EAE (Pollak et al.,
2003a).
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Accordingly, we recently linked EAE depressive-like behavior
to striatal IL-1β expression and dopaminergic system alterations
in the acute phase (Gentile et al., 2015). By studying mice
with mild-EAE phenotype, we demonstrated the occurrence of
depressive-like (TST and FST) and motivation-based behaviors
(nest building test-NB test) in the acute phase of the disease
in correlation with striatal and hippocampal microgliosis.
Since IL-1β was expressed by microglia in such areas but
the cytokine expression raised significantly in EAE striatum,
we hypothesized that IL-1β released by microglia in this
area may affect the dopaminergic system thus contributing
to EAE depressive-like behavior. Accordingly, the preventive
central treatment with IL-1ra corrected emotional changes as
well as defective striatal dopaminergic neurotransmission, thus
linking inflammation-induced neurotransmission alteration and
behavior.
Summarizing, TNF and IL1-β alter EAE behavior likely by
affecting catecholamine and glutamatergic neurotransmission in
several brain areas, pointing to microglia as possible cellular
mediator.
The Impact of MS Drugs on Behavioral
Outcomes: The Example of Glatiramer
Acetate and Interferon-1 Beta
Most of the drugs approved for MS therapy are
immunomodulatory or immunosuppressive agents, providing
to variable extent functional recovery. However, they may have
a strong impact on mood control, making necessary ad hoc
pharmacological interventions. Among the currently available
therapeutic approaches for MS treatment, interferon-1β
(IFNB) and glatiramer acetate (GA) are first-line disease-
modifying drugs. Unfortunately, there is some evidence that
IFNB treatment exacerbates depressive symptoms more likely
than GA (Pandya and Patten, 2002; Goëb et al., 2003; Arnett
and Randolph, 2006), therefore in patients with a history
of depression GA treatment is often preferred (Wilken and
Sullivan, 2007). However, this issue seems not entirely solved,
with some studies reporting no differences between IFNB and
GA (Kirzinger et al., 2013) or no significant beneficial effect of
GA on mood-related outcomes (Jongen et al., 2010).
Due to the restricted literature about EAE-linked behavioral
changes, it is clear that animal studies are far from succeeding
in clarifying this matter. Only one paper examined MS drug
impact on EAE anxiety-like behavior (Piras et al., 2013;
Table 1), correlating EAE emotional changes with time-
dependent increased peripheral lymphocytosis. The authors
observed that GA attenuated lymphocytosis and behavioral
impairment in a very early phase of the disease. Consistently,
we found that GA reduced anxiety-like behavior in pre-
symptomatic EAE mice (7 dpi) by OFT (Figures 1A,B).
We previously demonstrated that GA treatment protected
against the TNF-induced synaptotoxic effect on striatal
glutamatergic transmission by reducing microgliosis and
microglia expression of TNF in the striatum of acute-phase EAE
mice (Gentile et al., 2013). Interestingly, activated microglia
stimulated with GA in vitro mimicked the electrophysiological
effect of GA treatment in EAE mice. It has been supposed
that GA interacts with microglial surface proteins, involved
in microglia activation, like MHC-II complex (Fridkis-
Hareli et al., 1997) and P2X7 receptor (Caragnano et al.,
2012).
Therefore, we examined GA effect on striatal microglia
activation of pre-symptomatic mice. In accordance to our
previous findings (Haji et al., 2012), a strong microgliosis was
observed in pre-symptomatic EAE striatum (Figure 1C), while
GA induced additional proliferation of microglial cells with
a resting phenotype, suggesting reduced inflammation. The
microglial changes induced by GA may abolish the potentiated
glutamatergic transmission in the pre-symptomatic striatum,
through mechanisms similar to those described in the acute
phase. Also, in GA striatum we could occasionally observe
amoeboid-like microglial cells, resembling cells in phagocytic
activity (not shown): in vitro studies on primary murine
microglia and human monocytes have shown that GA promotes
phagocytosis in those cells (Pul et al., 2011, 2012), likely with
protective effects.
Lastly, PET studies in MS patients treated with GA
corroborate the effect of GA on microglial activation (Ratchford
et al., 2012).
Conclusions and Perspectives
The investigation of the role of microglia in MS pathogenesis
is flourishing, but the contribution of these cells to MS mood
disturbances has been only partially addressed. The analysis of
pre-symptomatic or non-disabled EAE mice allows dissecting
the different contribution of microglia to behavior and motor
symptoms.
From the above overview, several elements have emerged:
inflammation and microglia activation are involved in EAE-
behavioral syndrome and impaired neurotransmission is likely
the final outcome of the overactive microglia-immune-neuronal
interaction, leading to behavioral alterations. The interplay
between microglia and neurons is still poorly explored, but
promising and therapeutically attractive. Therefore, we propose
to further study the interaction between microglia activation
and neurotransmission in brain areas involved in mood control:
for example by investigating microglia contribution to EAE/MS
hippocampal synaptic dysfunctions (Dutta et al., 2013; Nisticò
et al., 2013; Michailidou et al., 2015), and by extending studies
in EAE striatum from glutamate and catecholamine to other
compromised neurotransmitter systems, such as GABA or
cannabinoids (Musumeci et al., 2011; Rossi et al., 2011; Musella
et al., 2014). Targeting microglia to limit synaptic damage
and behavioral distortion by using immunomodulatory agents,
such as GA, or the antibiotic minocycline, known to reduce
microgliosis and depressive symptoms (Hinwood et al., 2013),
may represent an alternative therapeutic strategy to conventional
anti-depressants.
The study of microglia should be fostered in experimental
as well as in human investigations and with regard to
mood etiology, by using novel in vivo imaging techniques.
Interestingly, the recent introduction of second-generation PET
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FIGURE 1 | Glatiramer acetate (GA) treatment protects from
EAE-induced anxiety-like behavior and attenuates microglia activation.
(A) Anxiety-like behavior was assessed in pre-symptomatic EAE mice (7 days
post immunization, dpi) by means of open field test (OFT). The time in the center
of the arena is reduced in EAE-vehicle mice compared to control CFA-vehicle
mice and significantly increased in GA-treated mice. CFA-vehicle mice are the
experimental control of EAE, receiving the same treatment of EAE mice with the
exception of the immunogen MOG35–55. Data are expressed as mean ± S.E.M.
One-way ANOVA analysis, Tukey’s post hoc test: EAE-GA vs. EAE-vehicle
###p < 0.001, EAE-vehicle vs. CFA-vehicle ***p < 0.001. (B) The total distance
traveled in the arena was unchanged among the groups, confirming the
absence of motor dysfunction in 7 dpi EAE mice. Data are expressed as mean
± S.E.M. One-way ANOVA analysis, Tukey’s post hoc test: EAE-vehicle vs.
CFA-vehicle p > 0.05; EAE-GA vs. EAE-vehicle p > 0.05; CFA-vehicle vs.
EAE-GA p > 0.05. (C) GA treatment affects microglia proliferation and
activation in the striatum of pre-symptomatic (7 dpi) EAE mice. The
microphotographs are low magnification confocal images showing microglial
cell density in the striatum of control CFA-vehicle, EAE-vehicle and EAE-GA
mice: Iba1 staining for microglia (red; counter-staining with DAPI–blue), reveals
increase in microglial cell density in EAE-vehicle vs. CFA-vehicle striatum with
further enhancement in EAE-GA striatum. Insets show different morphologies of
microglial cells among the groups: microglia from EAE striatum is visibly
hypertrophic if compared to both microglia from CFA-vehicle and EAE-GA
striatum. Scale bar: 25 µm. Quantitative and qualitative analysis of microglia,
based on IBA1 immunofluorescence, is reported down the immunofluorescence
images: GA increases microglia density and restores resting state of microglial
cells. The morphological analysis of microglial cells, based on the area covered
by IBA1 positive cells inside the striatum, shows the effect of GA in reducing
microglial hypertrophy observed in EAE-vehicle, expressed as mean cell area,
while the total microglial area is similar to EAE-vehicle microglia. For image
acquisition and analysis method, refer to Gentile et al., 2013. Data are
expressed as mean ± S.E.M. One-way ANOVA analysis, Tukey’s post hoc test:
EAE-vehicle and EAE-GA vs. CFA-vehicle: ***p < 0.001, **p < 0.01; EAE-GA
vs. EAE-vehicle: ###p < 0.001, #p < 0.05.
radioligands has been found able to reveal the extent ofmicroglial
activation by quantifying the increased expression of the 18-kDa
translocator protein (TSPO) in EAE (Mattner et al., 2013) and
MS (Giannetti et al., 2014, 2015) brains. The use of this technique
is not yet widespread for economic and safety reasons, but it
is viewed as highly promising for EAE/MS pathogenesis studies
(Politis et al., 2012b), as well as to monitor and to distinguish
drug effects on microgliosis (Airas et al., 2015) and to predict
clinical outcomes (Politis et al., 2012a). Increased TSPO binding
was observed in normal-appearing gray and white matters in
MS remitting patients (Versijpt et al., 2005), corroborating the
hypothesis that microglia activation occurs early in the disease
and can affect the neuronal compartment (Centonze et al.,
2010). The application of such technique to behavioral disorders
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is embryonic (Kenk et al., 2015): microglial metabolite PET
measurements could be correlated to data from psychological
assessment in MS or behavioral testing and electrophysiological
recordings in EAE.
To conclude, we are confident that the integration of data
from clinical and preclinical studies and the combined use of
different techniques for monitoring microglia state and action
are a fruitful strategy to find novel diagnostic and therapeutic
tools for MS mood-related disorders.
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